Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 62OTHER 47NIH 2OTHER_GOV 1NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Pathologic Complete Response 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1HER2 Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Breast Diseases 1Advanced Non-small-cell Lung Cancer 1Advanced Gastric Cancer 1

Interventions

Drug Therapy 4pembrolizumab 3Thermography 2Surveys and Questionnaires 2Standard of Care 2Quality of Life 2Preoperative Exercise 2Nivolumab 2Moxibustion 2Hematologic Tests 2Cyclophosphamide 2Chemoradiotherapy 2vandetanib 1sinovac COVID-19 vaccine 1lenvatinib 1ibrutinib 1fludarabine 1encorafenib 1durvalumab 1binimetinib 1beta Carotene 1avelumab 1atezolizumab 1Zoledronic Acid 1Zinc 1Vitamin E 1Vascular Access Devices 1Validation Studies as Topic 1Urination 1Ultraviolet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Neoplasms × Docetaxel × Clear all
NCT01472146 2017-05-09

ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Instituto Nacional de Cancer, Brazil

Phase 2 Completed
58 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡